<u>Instructions:</u> The Enrollment Form should be completed for each TCGA qualified case, upon qualification notice from the BCR. All information provided on this form should include activity from the date of initial diagnosis to the most recent date of contact with the patient ("Date of Initial Pathologic Diagnosis" and "Date of Last Contact" on this form).

Questions regarding this form should be directed to the Tissue Source Site's primary Clinical Outreach Contact at the BCR.

Please note the following definitions for the "Unknown" and "Not Evaluated" answer options on this form.

Unknown: This answer option should only be selected if the TSS cannot answer the question because the answer is not known at the TSS. If this answer option is selected for a question that is part of the TCGA required data set, the TSS must complete a discrepancy note providing a reason why the answer is unknown.

Not Evaluated: This answer option should be selected by the TSS if it is known that the information being requested cannot be obtained. If for example, a test was not performed the results of that test cannot be provided because it was "Not Evaluated."

Not Evaluated."							
issu	e Source Site (TSS):	TSS Unique Patient Identifier:					
omp	leted By (Interviewer Name	on OpenClinica):	Completed Date:				
General Information							
#	Data Element	Entry Alternatives	Working Instructions				
1	Is this a prospective tissue collection?	□ Yes □ No	Indicate whether the TSS providing tissue is contracted for prospective tissue collection. If the submitted tissue was collected for the specific purpose of TCGA, the tissue has been collected prospectively. 3088492				
2	Is this a retrospective tissue collection?	□ Yes □ No	Indicate whether the TSS providing tissue is contracted for retrospective tissue collection. If the submitted tissue was collected prior to the date the TCGA contract was executed, the tissue has been collected retrospectively. 3088528				
atie	nt Information						
#	Data Element	Entry Alternatives	Working Instructions				
Dat	e of Birth						
3	Date of Birth		Provide the date the patient was born. <u>2896950</u> (Month), <u>2896952</u> (Day), <u>2896954</u> (Year)				
4	Gender	Month Day Year ☐ Female ☐ Male	Provide the patient's gender using the defined categories. 2200604				
5	Race	 □ American Indian or Alaska Native A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. □ Asian	Provide the patient's race using the defined categories. 2192199				

Hawaii, Guam, Samoa, or other Pacific Islands.

Mesothelioma

#	Data Element	Entry Alternatives	Working Instructions				
		□ Not Evaluated Not provided or available. □ Unknown Could not be determined or unsure.					
6	Ethnicity	 Not Hispanic or Latino	Provide the patient's ethnicity using the defined categories. 2192217				
7	History of Other Malignancy	□ Yes □ No	Indicate whether the patient was, at any time in their life, diagnosed with a malignancy prior to the diagnosis of the specimen submitted for TCGA. If the patient has any history, including synchronous or bilateral malignancies, please complete an "Other Malignancy Form" for each malignancy diagnosed prior to the procurement of the tissue submitted for TCGA. If the OMF was completed and submitted with the Initial Case Quality Control Form, the OMF does not need to be submitted a second time. 3382736 If this question cannot be answered because the answer is unknown, please contact the BCR. If the patient has a history of multiple diagnoses of basal or squamous cell skin cancer, complete an OMF for the first diagnosis for each of these types.				
8	Neo-adjuvant (pre- operative) therapy for tumor submitted for TCGA	□ Yes □ No	Indicate whether the patient received neo-adjuvant treatment (radiation, pharmaceutical, or both) prior to the resection of the tumor that yielded the sample submitted for TCGA. 3382737 Systemic therapy and certain localized therapies (those administered to the same site as the TCGA submitted tissue) given prior to the resection of the sample submitted for TCGA is exclusionary.				
9	Was pleurodesis performed prior to cancer sample procurement?	□ Yes □ No □ Unknown	Indicate whether the patient received pleurodesis prior to the resection of the tumor submitted for TCGA. $\underline{3646078}$				
10	If pleurodesis was performed, was it performed at least 90 days prior to the cancer sample procurement?	□ Yes □ No □ Unknown	If the patient received pleurodesis, indicate whether the procedure was performed at least 90 days prior to the resection of the tumor sample submitted for TCGA. 3646080				
11	Tumor Status (at time of last contact or death)	☐ Tumor free ☐ With tumor ☐ Unknown	Indicate whether the patient was tumor/disease free at the date of last contact or death. 2759550				
12	Vital Status (at date of last contact)	☐ Living ☐ Deceased	Indicate whether the patient was living or deceased at the date of last contact. $\underline{5}$				
Date of Last Contact (If patient is living)							
13	Date of Last Contact		If the patient is living, provide the date of last contact with the patient (as reported by the patient, medical provider, family member, or caregiver). 2897020 (Month), 2897022 (Day), 2897024 (Year)				
		·					

Mesoth	nelioma
MESOLI	ICHOIHa

V4.17 080114

#	Data Element	Entry Alternatives			<u> </u>		Working Instructions	
Date	Date of Death							
14	Date of Death	- Marsell				-	If the patient is deceased, provide the date of death. 2897026 (Month), 2897028 (Day), 2897030 (Year)	
Dati	ent Occupation and Asb	Month	Day		Year			
15	Asbestos Exposure	☐ Yes ☐ No ☐ Unknown					Indicate whether the patient has asbestos exposure prior to the diagnosis of the tumor submitted for TCGA. 1253	
16	Type of Asbestos Exposure	☐ Chrysotile ☐ Anthophy ☐ Amosite ☐ Erionite		☐ Crocio ☐ Actin ☐ Trem ☐ Unkn	olite olite		If the patient had a known exposure to asbestos, indicate the type of asbestos exposure. 3629989	
17	Source of First Asbestos Exposure	☐ Occupation ☐ Secondary ☐ Unknown					If the patient had a known exposure to asbestos, indicate the source of the asbestos exposure. 3629990	
18	Age at First Asbestos Exposure	D OHRHOWN	Years				If the patient had known occupational and/or environmental asbestos exposure, indicate the patient's age at their first exposure. 3629991	
19	Number of Years of Asbestos Exposure			Years			If the patient had known occupational and/or environmental asbestos exposure, indicate the number of years of exposure. 3629992	
20	Age at Last Asbestos Exposure	Years					If the patient had a known exposure to asbestos, provide the age at last asbestos exposure. 3629993	
21	Primary Occupation	□ Asbestos Mining □ Construction □ Automotive □ Welding □ Unknown □ Other (please specify)					Provide the occupation in which the patient was employed for the majority of their working years. 3259240	
22	Other Primary Occupation						If the patient's primary occupation was not included in the list provided, specify the occupation in which the patient was employed for the majority of their working years. 5714	
23	Years Worked in Industry	Years					Provide the number of years the patient was employed in their primary occupation. $\underline{2435424}$	
24	Family History of Cancer	☐ Spouse ☐ Child ☐ Parent ☐ Sibling	Mesothelioma	Uveal Melanoma	Melanoma	Other (specify)	If the patient has a family history of cancer, provide the type of cancer of the patient's relative and their relationship to the patient. 2783641 (relative), 3838107 (type of cancer), 2691192 (other type of cancer),	
		□Grandparent □ Unknown						

#	Data Element	Entry Alternatives	Working Instructions
25	Performance Status Scale: Karnofsky Score	 □ 100 – Normal, no complaints, no evidence of disease □ 90 – Able to carry on normal activity; minor signs or symptoms of disease □ 80 – Normal activity with effort; some signs or symptoms of disease □ 70 – Cares for self, unable to carry on normal activity or to do active work □ 60 – Requires occasional assistance, but is able to care for most of his/her needs □ 50 – Requires considerable assistance and frequent medical care □ 40 – Disabled, requires special care and assistance □ 30 – Severely disabled, hospitalization indicated. Death not imminent. □ 20 – Very sick, hospitalization indicated. Death not imminent □ 10 – Moribund, fatal processes progressing rapidly □ 0 – Dead □ Unknown □ Not Evaluated 	Indicate the patient's Karnofsky performance status score at the time provided for the "Performance Status Score: Timing" question below. 2003853
26	Performance Status Scale: Eastern Cooperative Oncology Group (ECOG)	□ 0 – Asymptomatic □ 1 – Symptomatic but fully ambulatory □ 2 – Symptomatic but in bed less than 50% of the day □ 3 – Symptomatic and in bed more than 50% of the day □ 4 – Bedridden □ Unknown □ Not Evaluated	Indicate the patient's ECOG performance status score at the time provided for the "Performance Status Score: Timing" question below. 88
27	Performance Status Score: Timing	☐ Pre-Operative ☐ Post-Adjuvant ☐ Other	Provide the time reference for the Karnofsky score and/or the ECOG score using the defined categories. 2792763
28	Adjuvant (Post- Operative) Radiation Therapy	☐ Yes ☐ No ☐ Unknown	Indicate whether the patient had adjuvant/ post- operative radiation therapy. <i>IF the patient did have</i> <i>adjuvant radiation, the Radiation Supplemental Form</i> <i>should be completed</i> . 2005312
29	Adjuvant (Post-Operative) Pharmaceutical Therapy	☐ Yes ☐ No ☐ Unknown	Indicate whether the patient had adjuvant/ post- operative pharmaceutical therapy. If the patient did have adjuvant pharmaceutical therapy, the Pharmaceutical Supplemental Form should be completed. 3397567

#	Data Element	Entry Alternatives	Working Instructions
30	Primary Site of Disease	□ Pleura	Using the patient's pathology/laboratory report, select the anatomic site of disease of the tumor submitted for TCGA. 2735776
31	Laterality	☐ Left ☐ Right ☐ Bilateral	If applicable, indicate the laterality of the tumor that yielded the biospecimen submitted to for TCGA. 827
32	Histologic Subtype	☐ Epithelioid mesothelioma ☐ Sarcomatoid mesothelioma ☐ Desmoplastic mesothelioma ☐ Biphasic mesothelioma ☐ Diffuse malignant mesothelioma, NOS	Indicate the confirmed diagnosis of the tumor submitted for TCGA. 3081934

Enrollment FormMesothelioma

#	Data Element	Entry Alternatives	Working Instructions					
Date	Date of Initial Pathologic Diagnosis							
33	Date of Initial Pathologic Diagnosis	Month Day Year	Provide the date the patient was initially pathologically diagnosed with the malignancy submitted for TCGA. 2896956 (Month), 2896958 (Day), 2896960 (Year)					
AIC	C Staging	,						
34	AJCC Cancer Staging Edition Used At Initial Diagnosis	□ 1 st Edition (1978-1983) □ 2 nd Edition (1984-1988) □ 3 rd Edition (1989-1992) □ 4 th Edition (1993-1997) □ 5 th Edition (1998-2002) □ 6 th Edition (2003-2009) □ 7 th Edition (2010-present)	Please select the AJCC Cancer Staging Edition used to answer the following questions (#s 40-44). 2722309					
35	Primary Tumor (T) (per Staging Edition Indicated)	□ TX □ T1b □ T0 □ T2 □ T1 □ T3 □ T1a □ T4	Provide the AJCC T category of the primary tumor at initial diagnosis 3045435					
36	Regional Nodes (N) (per Staging Edition Indicated)	□ NX □ N2 □ N3 □ N1	Provide the AJCC N category at initial diagnosis 3203106					
37	Distant Metastasis (M) (per Staging Edition Indicated)	□ MX □ M0 □ M1	Provide the AJCC M category at initial diagnosis. 3045439					
38	Tumor Stage (per Staging Edition Indicated in)	☐ I ☐ II ☐ II ☐ III ☐ IB ☐ IV	Provide the overall AJCC stage at initial diagnosis. 3203222					
39	Residual Tumor	□ RX □ R0 □ R1 □ R1	Using the patient's pathology/laboratory report, select the tissue margin status at time of surgical resection. 2608702					
Tes	Tests Performed							
40	Serum mesothelin (SM) (prior to treatment)	(nmol/L)	Provide the patient's serum mesothelin level prior to treatment. $\underline{3629985}$					
41	Serum mesothelin (SM) Lower Limit	(nmol/L)	Provide the institution's lower serum mesothelin limit. $\frac{3629986}{}$					
42	Serum mesothelin (SM) Upper Limit	(nmol/L)	Provide the institution's upper serum mesothelin limit. $\frac{3629987}{}$					
43	Creatinine (prior to treatment)	(mg/dL)	Provide the patient's creatinine level prior to treatment. 58318					
44	Creatinine Lower Limit	(mg/dL)	Provide the institution's lower creatinine limit. 2234697					
45	Creatinine Upper Limit	(mg/dL)	Provide the institution's upper creatinine limit. $\underline{2004064}$					
46	Maximum SUV of Pleura (prior to treatment)		Provide patient's maximum standardized update value (SUV) of the Pleura. 2716767					
47	Detection Method of Mesothelioma	☐ Cytology ☐ Biopsy ☐ Thorascopy ☐ Thoracentesis	Indicate the method used to detect the patient's mesothelioma. 3629988					

Mesothelioma

New Tumor Event Information Complete this section if the patient had a new tumor event. If the patient did not have a new tumor event (or if the TSS does not know) indicate this in the question below, and the remainder of this section can be skipped.

#	Data Element	Entry Alternatives			Working Instructions	
48	New Tumor Event After Initial Treatment?	☐ Yes ☐ No ☐ Unknown			Indicate whether the patient had a new tumor event (e.g. metastatic, recurrent, or new primary tumor) after the date of initial diagnosis. For mesothelioma, recurrent tumor is local progression in or adjacent to the original cavity and metastati means disease outside the original pleural cavity. 3121376	
					If the patient did not have a new tumor event or if this is unknown, the remaining questions can be skipped.	
Date	e of New Tumor Event after	Initial Treatme	nt			
<u>49</u>	Date of New Tumor Event	Month	Day Y	 'ear	If the patient had a new tumor event, provide the date of diagnosis for this new tumor event. 3104044 (Month), 3104042 (Day), 3104046 (Year)	
<u>50</u>	Type of New Tumor Event	☐ Intrapleura☐ Distant Met☐ New Prima	astasis		Indicate whether the patient's new tumor event was progression in the same pleura, a distant metastasis or a new primary tumor. 3119721	
<u>60</u>	Site of New Tumor Event	☐ Bone ☐ Lung ☐ Liver ☐ Brain	☐ Ipsilateral pl ☐ Contralatera ☐ Abdomen ☐ Unknown ☐ Other, specif	ıl pleura	If the patient had a new tumor event, provide the site of this tumor. 3108271	
<u>61</u>	Other Site of New Tumor Event				If the site of the new tumor event is not included in the provided list, describe the site of this new tumor event. 3128033	
<u>62</u>	Additional Surgery for New Tumor Event	☐ Yes ☐ No ☐ Unknown			Using the patient's medical records, indicate whether the patient had surgery for the new tumor event in question. 3427611	
Date	e of Additional Surgery for I	New Tumor Ever	nt (when applicable)			
<u>63</u>	Date of Additional Surgery for New Tumor Event	 Month		 'ear	If the patient had surgery for the new tumor event, provide th date this surgery was performed. 3427612 (Month), 3427613 (Day), 3427614 (Year)	
<u>64</u>	Additional treatment for New Tumor Event: Radiation Therapy	☐ Yes ☐ No ☐ Unknown	,		Indicate whether the patient received radiation treatment for this new tumor event. 3427615	
<u>65</u>	Additional treatment for New Tumor Event: Pharmaceutical Therapy	☐ Yes ☐ No ☐ Unknown			Indicate whether the patient received pharmaceutical treatment for this new tumor event. 3427616	
					/	
Prin	cipal Investigator or Desig	nee Signature		Print Name	Date	